CD19 and B-cell non-Hodgkin lymphoma: Early timepoint studies (48 h after tracer administration on day 5 after CAR T cells administration) demonstrated the ability of tracking the CD19 CAR T cells to migrate to their target tissue, bone marrow bearing CD19 antigen on infiltrating B-cell lymphoma cells.